Ignite Creation Date:
2024-05-06 @ 1:40 PM
Last Modification Date:
2024-10-26 @ 1:18 PM
Study NCT ID:
NCT04092764
Status:
COMPLETED
Last Update Posted:
2022-11-07
First Post:
2019-09-13
Brief Title:
Feasibility Study for Electroacupuncture for Chemotherapy- Induced Peripheral Neuropathy CIPN
Sponsor:
H Lee Moffitt Cancer Center and Research Institute
Organization:
H Lee Moffitt Cancer Center and Research Institute
Study Overview
Official Title:
Feasibility Study for Electroacupuncture for Chemotherapy- Induced Peripheral Neuropathy CIPN Using a Point-Of-Nerve Conduction Device NeuroMetrix and the Rydel-Seiffer Tuning Fork
Status:
COMPLETED
Status Verified Date:
2022-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to determine the validity of a point-of-care nerve conduction device NeuroMetrix and Rydel-Seiffer tuning fork in assessing the level of peripheral neuropathy in patients with chemotherapy-induced peripheral neuropathy CIPN Chemotherapy-induced peripheral neuropathy CIPN is a common persistent toxicity among patients who receive chemotherapy It is characterized by a variety of sensory and motor symptoms such as numbness tingling reduced sense of touch reduced proprioception awareness of your limb and body position in space pain weakness balance disturbances and deficits in motor skills
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None